Morphinan Derivative Crystallization via Mixed Solvent Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing production methods for 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[N-methyl-trans-3-(3-furyl)acrylamido]morphinan hydrochloride result in amorphous forms with inconsistent quality and low purity due to crystal polymorphism, leading to unpredictable potency and stability issues in medicinal applications.
Innovation Solution
A process involving the reaction of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-6β-[N-methyl-trans-3-(3-furyl)acrylamido]morphinan with hydrochloric acid in a good solvent, followed by mixing with a poor solvent and stirring, specifically using methanol and 2-propanol, to produce a consistent crystal form with high purity and low cis isomer content.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If the compound is produced by conventional methods, then production is achieved, but the compound forms amorphous structures with inconsistent quality and low purity
Solution Approach 1:
The invention changes the solvent system parameters by using a mixed solvent system (first solvent: second solvent in specific volume ratios) instead of conventional single solvents. This parameter change induces the formation of specific crystal forms (A-form, B-form, or C-form) with consistent quality and high purity, resolving the issue of amorphous structure formation
Solution Approach 2:
The invention utilizes phase transition from amorphous to crystalline state by controlling crystallization conditions in the mixed solvent system. The specific solvent combination and volume ratios promote nucleation and crystal growth, transforming the compound from amorphous form to well-defined crystal forms with consistent properties
2Adaptability or versatility
If crystal polymorphism is present, then different crystal forms exist, but solubility and stability vary leading to unpredictable potency
Solution Approach 1:
The invention applies local quality by providing specific crystal forms (A-form, B-form, C-form) with distinct and consistent local molecular arrangements. Each crystal form has defined solubility and stability characteristics, allowing selection of the appropriate form for specific medicinal applications while ensuring predictable potency
Solution Approach 2:
The invention performs preliminary action by establishing specific crystallization conditions (solvent system and volume ratios) that pre-determine the formation of desired crystal forms. This preliminary control of crystallization parameters ensures that the compound consistently forms the intended crystal structure, enabling reliable potency prediction
3Productivity
If amorphous form is produced, then production is achieved, but purity is low and quality is inconsistent
Solution Approach 1:
The invention changes the crystallization parameters by employing a mixed solvent system with specific volume ratios, which promotes the formation of high-purity crystal forms during the production process. This parameter optimization maintains production efficiency while achieving consistent high purity and quality
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method ensures a crystal form with consistent quality, high purity, and stable pH, addressing the issues of crystal polymorphism and potency variability, resulting in a reliable active ingredient for medicinal use.
Implementation Method 1
mixing the reaction solution with a poor solvent and stirring the mixture
Implementation Method 2
the good solvent is selected from the list consisting of methanol, ethanol and n-propanol and the poor solvent is selected from the list consisting of 2-propanol, 2-butanol and t-butanol
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention is directed to provide 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[N-methyl-trans-3-(3-furyl)acrylamido]morphinan hydrochloride consistent in quality after production and having high purity. A crystal of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[N-methyl-trans-3-(3-furyl)acrylamido]morphinan hydrochloride including a A-form, B-form or C-form crystal thereof, and a process for producing the same are provided.